Skip to main content
BioCentury on BioBusiness
Feature Story

Strategy: Eurosimilars

Why it's hard to extrapolate European biosimilars market penetration to the U.S.

By Steve Usdin, Washington Editor

The complex European biosimilars landscape makes it hard to extrapolate pricing, market share and switching trends to the U.S.

Across Europe, price reductions following biosimilar introduction vary widely. For example, according to IMS Health Inc., the introduction of biosimilar epoetin products led to prices decreasing 55% in Germany, 39% in France, 24% in Spain and 18% in the U.K.

Read Article
  • THE DISTILLERY brings you this week's most essential scientific findings in therapeutics, distilled by Innovations editors from a weekly review of more than 400 papers in 41 of the highest-impact journals in the fields of biotechnology, the life sciences and chemistry. The Distillery goes beyond the abstracts to explain the commercial relevance of featured research, including licensing status and companies working in the field, where applicable.

    This week in therapeutics includes important research findings on targets and compounds, grouped first by disease class and then alphabetically by indication.

    This week in techniques includes findings about research tools, disease models and manufacturing processes that have the potential to enable or improve all stages of drug discovery and development.

Subscribe Now
Free Trial